Further studies are also needed to focus on the involvement of the PI3K/AKT pathway in E2F1/miR-375/SESN3-mediated ESCC progression with PI3K/AKT inhibitors. The gene discussed is E2F1; the disease is esophageal squamous cell carcinoma.